HARP News and Press, Harpoon Therapeutics Inc. From 09/13/23

2023-09-13 17:22:37 ET More on Harpoon Therapeutics Seeking Alpha’s Quant Rating on Harpoon Therapeutics Historical earnings data for Harpoon Therapeutics Financial information for Harpoon Therapeutics For further details see: Harpoon up even as Ab...

2023-09-13 17:07:09 ET Gainers: The Kraft Heinz  ( KHC ) +6% . CareDx ( CDNA ) +5% . Payoneer Global ( PAYO ) +5% . Microvast Holdings ( MVST ) +4% . Fate Therapeutics ( FATE ) +4% . Losers: IBEX Limited ( IBEX )...

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of...

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg co...

KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for poster presentation at the European Society for Medical Oncology (ESMO) being held October 20-24, 2023 SOUTH SAN FRAN...

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences in September. Citi ...

2023-08-31 08:17:07 ET Dollar General DG -16% after Q2 release . OKYO Pharma ( OKYO ) -14% . Top KingWin ( TCJH ) -10% . ReTo Eco-Solutions ( RETO ) -11% . Beneficient ( BENF ) -10% . Digital Brands Group ( DBGI ) -9% . ...

2023-08-09 17:41:32 ET Harpoon Therapeutics press release ( NASDAQ: HARP ): Q2 GAAP EPS of $0.03 beats by $0.37 . Revenue of $20.22M (+143.6% Y/Y) beats by $15.08M . For further details see: Harpoon Therapeutics GAAP EPS of $0.03 beats by $0.37, revenue o...

Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society (IMS) Annual Meeting and the European Society for Medical Oncology (ESMO) in the fall Enrollment for HPN328 (DLL3) ongoing; Phase 2 dose selection expected by year end Completed plann...

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in two upcoming investor conferences: A corporate presentatio...